Naive CD8+ T cells can be activated via dendritic cell 'cross-priming' of antigens obtained exogenously. Dendritic cells cannot cross-prime, however, after systemic activation in vivo, potentially contributing to immunosuppression associated with severe infections.
This is a preview of subscription content, log in via an institution to check access.
Katie Ris
References
Heath, W.R. et al. Immunol. Rev. 199, 9–26 (2004).
Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C. & Amigorena, S. Annu. Rev. Immunol. 20, 621–667 (2002).
Wilson, N.S. et al. Nat. Immunol. 7, 165–172 (2006).
Pozzi, L.A., Maciaszek, J.W. & Rock, K.L. J. Immunol. 175, 2071–2081 (2005).
Yewdell, J.W. & Hill, A.B. Nat. Immunol. 3, 1019–1025 (2002).
Yewdell, J.W. & Haeryfar, S.M. Annu. Rev. Immunol. 23, 651–682 (2005).
Pierre, P. Immunol. Rev. 207, 184–190 (2005).
Herter, S. et al. J. Immunol. 175, 891–898 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hickman-Miller, H., Yewdell, J. Youth has its privileges: maturation inhibits DC cross-priming. Nat Immunol 7, 125–126 (2006). https://doi.org/10.1038/ni0206-125
Issue Date:
DOI: https://doi.org/10.1038/ni0206-125
- Springer Nature America, Inc.
This article is cited by
-
Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
Journal of Translational Medicine (2020)
-
Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy
Cancer Immunology, Immunotherapy (2013)